euro-infectious-diseases-2017-posters-accepted-abstracts

7 / 33

Page 59
Notes:
conferenceseries.com
Volume 5, Issue 6(Suppl) J Infect Dis Ther, an open access journal
ISSN: 2332-0877 Euro Infectious Diseases 2017
September 07-09, 2017
September 07-09, 2017 | Paris, France
Infectious Diseases
6th Euro-Global Conference on
Frequency of rrs and rpsLmutations in streptomycin-resistant isolates of Mycobacterium tuberculosis
from Iranian patients
Azar Dokht Khoravi, Nayereh Etemad, Mohammad Hashemzadeh, Solmaz Khandan Dezfuli and Hamed Goodarzi
Ahvaz Jundishapur University of Medical Sciences, Iran
S treptomycin (SM) is one of the most effective drugs for the treatment of multidrug resistant (MDR) TB. However, resistance
to SM is increasingly reported mainly due to mutations in rpsL and rrs genes. The present study was designed with the
aim to determine the nature of SM resistance and the type and frequency of rpsL and rrs mutations among SM resistant
Mycobacterium tuberculosis (MTB) isolates from Iran. One hundred clinical mono and multidrug-resistant MTB isolates
were subjected to drug susceptibility testing (DST) for SM. SM resistant isolates were genotyped by using MIRU-VNTR typing.
Fragments of the rpsL and rrs genes were amplified to investigate the most common mutations with subsequent sequence
analysis. By DST, 32 (32%) isolates were identified as SM resistant, of which, 43.7% (14/32) were MDR. By MIRU-VNTR
typing, the SM resistant isolates were classified into 20 different MIRU types and 8 clusters, with Beijing (39.13%) as the most
prevalent genotype. Mutations in the rrs and rpsL genes were identified in 14 (43%) and 10 (31%) of the SM resistant isolates
respectively. The most common mutations were at codon 128 (AAG→AGG, Lys43Arg), found in 7 (21%) isolates, and at codon
263 (A→G, Lys88Arg) in 3 (9%) isolates. The results suggest an association between the rpsL mutation and SM resistant strains
of the Beijing genotype. The existence of 25% SM resistance in the isolates without mutation in rrs and rpsL genes, suggests the
occurrence of further mechanisms associated with SM resistance in the isolates.
Biography
Azar Dokht Khoravi has her expertise in Mycobacteria genotyping and drug resistance. Her work in this field was started from her PhD course in University College
London, where she had the opportunity to work with known scientists in this field Professors John Stanford and Graham Rook as her supervisors. Since Iran is an
endemic country for tuberculosis, she and his colleagues and graduate students have recently established a research area in southwestern Iran linked with the
public health tuberculosis reference laboratory which is under the WHO supervision, focusing on the drug resistance in M. tuberculosis. This is a promising area
with the aim to minimize the rate of MDR tuberculosis in collaboration with health sectors for an improved treatment management of tuberculosis.
Azar Dokht Khoravi et al., J Infect Dis Ther 2017, 5:6(Suppl)
DOI: 10.4172/2332-0877-C1-033